1. Spark Therapeutics for gene therapies to cure blindness.

2. Regeneron, but focused on gene therapies to cure blindness.

• OCU400: A gene therapy candidate aimed at restoring retinal function for inherited retinal diseases, including retinitis pigmentosa and Leber congenital amaurosis.
• OCU410: A gene therapy candidate in development for the treatment of dry age-related macular degeneration (AMD).
• OCU200: A preclinical fusion protein candidate designed to treat diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration (AMD).
• COVAXIN: A COVID-19 vaccine that Ocugen is commercializing in the United States market.

Ocugen, Inc. is a clinical-stage biopharmaceutical company, meaning its primary focus is on the research and development of gene therapies, and its own pipeline products are not yet approved for commercial sale. Therefore, it does not currently have major commercial customers for its proprietary gene therapies.

However, Ocugen has a strategic partnership with Bharat Biotech for the commercialization of COVAXIN (a vaccine) in the United States market. Through this agreement, if Ocugen is the entity selling COVAXIN in the U.S., its major customers would be institutional buyers rather than individuals. These customers would primarily fall into the following categories:

• Hospitals and Healthcare Systems: These are organizations responsible for patient care, including the procurement and administration of vaccines to patients and staff.
• Pharmacy Chains: Major retail pharmacy networks that purchase, store, and administer vaccines to the public. Examples of such public companies include CVS Health (CVS) and Walgreens Boots Alliance (WBA).
• Government Health Agencies: Federal, state, and local government bodies responsible for public health initiatives, which often procure vaccines for widespread vaccination programs.

• CanSino Biologics Inc. (6185.HK)
• Bharat Biotech

Shankar Musunuri, Chief Executive Officer

Shankar Musunuri is the Co-founder, Chairman, and Chief Executive Officer of Ocugen, having served as Chairman since 2013 and CEO since May 2015. He has over 30 years of experience in advancing and commercializing diverse products within the biotech and pharmaceutical industry. Prior to co-founding Ocugen, Dr. Musunuri founded and served as President and CEO of Nuron Biotech, Inc., which became a commercial company in under three years. He also spent nearly 15 years at Pfizer, where he held various leadership roles, including Global Operations Team Leader for the successful launch of the Prevnar 13® vaccine. His earlier career included work at Amylin Pharmaceuticals. Dr. Musunuri holds a Ph.D. in Pharmaceutical Sciences from the University of Connecticut and an MBA from Duke University's Fuqua School of Business.

Rita Johnson-Greene, Chief Financial Officer

Rita Johnson-Greene was appointed Chief Financial Officer of Ocugen on February 9, 2026, bringing over 20 years of healthcare experience to the role. She most recently served as Chief Operating Officer at the Alliance for Regenerative Medicine, where she was responsible for operations, finance, and global expansion initiatives. Her background also includes leadership positions at Genetix Biotherapeutics (formerly bluebird bio), where she built pre-commercial teams for gene therapy launches, and senior roles at Spark Therapeutics and AstraZeneca. Ms. Johnson-Greene began her career in strategic consulting at Accenture. She earned an MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania and an undergraduate degree in Electrical Computer Engineering from Drexel University.

Arun Upadhyay, Chief Scientific Officer

Arun Upadhyay serves as the Chief Scientific Officer at Ocugen. He earned his Ph.D. in bioscience and bioengineering from the Indian Institute of Technology in Jodhpur, India, where his doctoral research focused on the molecular pathways of proteostasis. Dr. Upadhyay previously held a position as an Assistant Professor at the Central University of Rajasthan in India. He also conducted research at Northwestern University in Chicago, investigating the structural and proteomic composition of amyloid fibril cores in Alzheimer's disease.

Huma Qamar, Chief Medical Officer

Huma Qamar is the Chief Medical Officer at Ocugen. She is 41 years old.

Ramesh Ramachandran, Chief Accounting Officer

Ramesh Ramachandran holds the position of Chief Accounting Officer at Ocugen. He previously served as the principal financial officer until Rita Johnson-Greene's appointment as CFO, at which point he remained as Chief Accounting Officer and principal accounting officer.

Key Risks for Ocugen (OCGN)

1. Clinical Trial and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Ocugen's success is heavily dependent on the successful completion of preclinical and clinical trials for its pipeline products (e.g., OCU400, OCU410, OCU200) and subsequent regulatory approvals. Failure to demonstrate efficacy and safety, or experiencing delays in trials or regulatory processes, could significantly impede the company's ability to bring products to market and generate revenue.
2. Product Development and Commercialization Challenges for Gene Therapies: Even with successful clinical trials and regulatory approvals, gene therapies present unique development and commercialization challenges. These include complex and costly manufacturing processes, potential difficulties in achieving market adoption, securing favorable reimbursement policies, and navigating competition in the specialized field of inherited retinal diseases and age-related macular degeneration.
3. Dependence on a Limited Product Pipeline: Ocugen's future growth and financial performance are largely tied to the success of a concentrated pipeline of gene therapy candidates. The company's primary focus is on a few key assets, such as OCU400 for inherited retinal diseases and OCU410 for dry age-related macular degeneration. The failure of one or more of these core candidates could have a substantial negative impact on the company's long-term viability and growth prospects.

The highly saturated and evolving market for COVID-19 vaccines in the United States poses a significant emerging threat to Ocugen's partnership with Bharat Biotech for the commercialization of COVAXIN. The market is largely dominated by established mRNA vaccine platforms from companies like Pfizer and Moderna, and demand has shifted from initial vaccinations to booster shots for evolving variants. This makes it extremely challenging for a new, non-mRNA vaccine to gain regulatory approval and achieve meaningful market penetration.

Ocugen, Inc. (OCGN) focuses on developing gene therapies for blindness diseases. The addressable markets for its main products are as follows:

OCU400 (Gene therapy for inherited retinal diseases, including retinitis pigmentosa and Leber congenital amaurosis)

• Inherited Retinal Diseases (overall): The global inherited retinal diseases market size was valued at USD 21.74 billion in 2024 and is expected to reach USD 39.94 billion by 2032. Another estimate indicates the global inherited retinal disease market reached US$ 1.25 billion in 2025 and is projected to reach US$ 2.78 billion by 2032. The U.S. Inherited Retinal Diseases Treatment Market is estimated at USD 4.7 billion in 2025, with a projected increase to USD 9.4 billion by 2035.
• Retinitis Pigmentosa: The global retinitis pigmentosa market is predicted to grow from USD 14.89 billion in 2024 to USD 27.17 billion by 2034. In the United States, the total Retinitis Pigmentosa Treatment Market Size was estimated at approximately USD 260 million in 2023. The market size for retinitis pigmentosa across the 7MM (United States, EU4, United Kingdom, and Japan) was about USD 500 million in 2023.
• Leber Congenital Amaurosis: The global Leber congenital amaurosis market size was valued at USD 1.01 billion in 2024 and is projected to grow to USD 1.34 billion in 2029. Other reports value the global market at USD 71.04 million in 2024, expected to reach USD 103.04 million by 2032, and at USD 1.3 billion in 2024, projected to reach USD 2.14 billion by 2035. North America was identified as the largest region in this market in 2024.

OCU410 (Gene therapy for dry age-related macular degeneration - AMD)

• Dry Age-Related Macular Degeneration (AMD), specifically Geographic Atrophy (GA): Geographic atrophy, the advanced stage of dry AMD, affects approximately 2-3 million people in the United States and Europe. The global dry age-related macular degeneration market size was valued at USD 1.89 billion in 2024 and is projected to reach USD 3.51 billion by 2033. In 2023, the total Dry AMD market size in the 7MM was approximately USD 1.3 billion, with the U.S. market estimated at around USD 800 million.

OCU200 (Fusion protein for diabetic macular edema, diabetic retinopathy, and wet AMD)

• Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet AMD (combined): Approximately 12 million people in the United States and 130 million people worldwide are affected by DME, DR, or wet AMD.
• Diabetic Macular Edema (DME): The global Diabetic Macular Edema Market is estimated to be valued at USD 4.20 billion in 2025 and is expected to reach USD 4.40 billion by 2030. Another projection indicates growth from USD 4.2 billion in 2025 to USD 4.7 billion by 2035. The market size reached USD 5.4 billion in 2023 and is expected to reach USD 7.5 billion by 2034.
• Diabetic Retinopathy (DR): The global diabetic retinopathy market size was estimated at USD 9.48 billion in 2024 and is expected to grow to USD 14.31 billion by 2031. Other estimates place the global market at USD 10.14 billion in 2025, growing to USD 18.97 billion by 2035, and at USD 10.71 billion in 2026, reaching USD 14.52 billion by 2031. North America held the largest revenue share in the global diabetic retinopathy market in 2024.
• Wet Age-Related Macular Degeneration (AMD): The global wet age-related macular degeneration (AMD) market size was USD 10.6 billion for 2025 and is projected to reach USD 16.7 billion by 2032. The global age-related macular degeneration market was valued at USD 10.1 billion in 2024, with the wet AMD segment dominating with USD 9.4 billion in 2024. North America sees approximately 200,000 new cases of wet AMD annually.

Here are 3-5 expected drivers of future revenue growth for Ocugen (OCGN) over the next 2-3 years:

1. Commercialization of OCU400 for Retinitis Pigmentosa: Ocugen's lead gene therapy candidate, OCU400, is a significant expected driver. The Phase 3 liMeliGhT trial has completed enrollment, with top-line data anticipated in the first quarter of 2027. A rolling Biologics License Application (BLA) submission is planned for the third quarter of 2026, with potential commercialization projected for 2027. This timeline positions OCU400 to generate substantial product revenue within the specified timeframe.
2. Advancement and Potential Commercialization of OCU410ST for Stargardt Disease: OCU410ST is another key gene therapy candidate progressing rapidly through clinical trials. The Phase 2/3 GARDian3 trial is reportedly ahead of schedule, with interim data expected in the third quarter of 2026 and top-line data in the second quarter of 2027. Following these milestones, a BLA submission will occur. Furthermore, alignment with the European Medicines Agency (EMA) for a single U.S.-based trial streamlines its development and potential entry into the European market, contributing to future revenue.
3. Strategic Partnerships and Licensing Agreements for Gene Therapy Pipeline: Ocugen is actively pursuing and securing strategic partnerships and licensing agreements for its gene therapy candidates. An example is the exclusive licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea, which includes potential near-term payments of up to $11 million. These types of agreements provide non-dilutive capital, upfront payments, development milestones, and future royalties on sales, serving as an important revenue stream even before direct commercialization in major markets.
4. Advancement of OCU410 for Geographic Atrophy (Dry Age-Related Macular Degeneration): While commercialization for OCU410 is likely beyond the immediate 2-3 year window, its continued advancement through clinical stages is a crucial driver of future value and potential revenue. The program has shown positive preliminary 12-month Phase 2 data, demonstrating a 46% reduction in lesion growth. Ocugen plans to initiate a Phase 3 trial for OCU410 in 2026. Successful progression through these trials increases the asset's overall value, making it more attractive for potential collaborations or eventual market entry, thereby laying groundwork for significant revenue growth in the longer term.

Share Repurchases

• Ocugen repurchased 121,500 shares for $0.05 million under a buyback program announced on October 9, 2019, with no shares repurchased between July 1, 2025, and September 30, 2025.

Share Issuance

• In January 2026, Ocugen completed an underwritten public offering of 15 million shares of common stock at $1.50 per share, generating gross proceeds of $22.5 million and net proceeds of approximately $20.85 million.
• In August 2025, the company secured $20 million through a registered direct offering of common stock and warrants with Janus Henderson Investors.
• Ocugen may receive up to an additional $30 million in gross proceeds from the August 2025 offering if the associated warrants are fully exercised.

Inbound Investments

• The $22.5 million financing in January 2026 was led by RTW Investments, with additional participation from new and existing investors.
• Ocugen signed a binding term sheet with Kwangdong Pharmaceutical for exclusive rights to OCU400 in South Korea, including potential near-term payments up to $11 million.

Capital Expenditures

• Proceeds from the January 2026 $22.5 million offering are intended to be used for general corporate purposes, including capital expenditures and working capital.
• The company's capital allocation has been primarily focused on funding the development of its gene therapy pipeline, with research and development expenses totaling $39.8 million for the full year 2025, compared to $32.1 million in 2024.